Evidence map›Paper›PMID 27512683›Full record

ReviewOncolytic virotherapy2015

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Nicolas As Sokolowski, Helen Rizos, Russell J Diefenbach

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncolytic virotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  4. Review
  5. Article
  6. HSV: The scout and assault for digestive system tumors.Frontiers in molecular biosciences · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Developing oncolyticIranian journal of basic medical sciences · 2020
    Article
  15. Perspectives on immunotherapy via oncolytic viruses.Infectious agents and cancer · 2019
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicolas As SokolowskiCentre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.
Helen RizosDepartment of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW, Australia.
Russell J DiefenbachCentre for Virus Research, Westmead Millennium Institute for Medical Research, The University of Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virotherapy exploits the properties of human viruses to naturally cytolysis of cancer cells. The human pathogen herpes simplex virus (HSV) has proven particularly amenable for use in oncolytic virotherapy. The relative safety of HSV coupled with extensive knowledge on how HSV interacts with the host has provided a platform for manipulating HSV to enhance the targeting and killing of human cancer cells. This has culminated in the approval of talimogene laherparepvec for the treatment of melanoma. This review focuses on the development of HSV as an oncolytic virus and where the field is likely to head in the future.

Indexed as

cancercombination therapyherpes simplex virusimmunityoncolysis

Identifiers

PMID27512683
PMCPMC4918397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.